Detailed Coverage

India Glycols Sees 56% Net Profit Jump in FY26, Plans Business Demerger

Net profit for FY 2025-26 stands at ₹282.33 crore, a significant increase from ₹180.38 crore in FY 2024-25.
Standalone gross sales and other income grew 9.0% to ₹9,869.71 crore in FY 2025-26 from ₹9,052.37 crore.

Reader Takeaway: Strong profit growth driven by spirits offsets chemical margin pressure; demerger aims for focused value creation.

What just happened

India Glycols announced robust financial results for the fiscal year ending March 31, 2026 (FY 2025-26). The company's net profit surged by 56.5% to ₹282.33 crore, up from ₹180.38 crore in the previous fiscal year. This significant profit jump was accompanied by a 9.0% increase in standalone gross sales and other income, reaching ₹9,869.71 crore. The company's board also approved a scheme to demerge its Bio Pharma and Spirits & Biofuel undertakings into separate entities, Ennature Bio Pharma Limited and IGL Spirits Limited, respectively.

Why this matters

The strong profit growth, outpacing revenue growth, indicates improved operational efficiencies and a successful strategy of focusing on higher-margin products, particularly in the potable spirits segment. The proposed demerger could unlock value by creating more focused businesses, potentially leading to better operational clarity and distinct market valuations for the demerged units. This strategic move is aimed at enhancing shareholder value.

The backstory

India Glycols has been navigating a competitive market landscape, with challenges in the Glycols segment due to price volatility in Monoethylene Glycol (MEG). The company has been strategically shifting its focus towards its Potable Spirits business, which has become the largest revenue contributor. In August 2025, the company also executed a share split to enhance liquidity and investor participation. Prior to the fiscal year-end, it successfully raised ₹466.99 crore through a preferential issue, utilizing the funds for working capital and debt reduction.

What changes now

The approved demerger scheme is pending approval from the National Company Law Tribunal (NCLT). If approved, it will lead to the creation of two distinct listed entities, allowing each business segment to pursue its strategic objectives with greater autonomy. The company's focus will likely be on streamlining operations within each new entity and managing the transition effectively. The share split aims to make the stock more accessible to a wider investor base.

Risks to watch

Investors should remain aware of the intense competition in the Glycols market and the ongoing price volatility of MEG, which can pressure profit margins. Geopolitical risks, particularly the ongoing Middle East conflict, could potentially disrupt supply chains and impact demand. The successful completion and execution of the demerger are also critical factors to monitor.

Peer comparison

While specific peer data for FY26 is not provided in the filing, India Glycols operates in diverse segments. Its Potable Spirits division competes with established Indian liquor companies. The Bio-Fuel segment is part of India's growing renewable energy push, competing with other biofuel producers. The Performance Chemicals segment faces competition from domestic and international chemical manufacturers.

Context metrics (time-bound)

• Revenue FY 2025-26: ₹9,869.71 crore (up 9.0% from FY 2024-25)
• Net Profit FY 2025-26: ₹282.33 crore (up 56.5% from FY 2024-25)
• EPS FY 2025-26: ₹44.31 (up 52.1% from FY 2024-25)
• Funds raised via Preferential Issue: ₹466.99 crore
• Share Split: August 2025 (₹10 to ₹5 face value)

What to track next

Investors should closely monitor the NCLT's decision on the demerger scheme. Progress in integrating the preferential issue funds for working capital and debt reduction will be important. Continued performance of the Potable Spirits and Bio-Fuel segments, alongside management's ability to mitigate risks in the chemical segment and global geopolitical uncertainties, will be key areas to watch.